Thymalfasin in the treatment of hepatitis B and C.
Ciancio. A A; Rizzetto. M M
Key Findings
- Thymalfasin has both immune‑modulating and direct antiviral actions.
- Small pilot trials in chronic hepatitis B showed about a 70% sustained response when added to interferon or nucleoside analogues.
- In hepatitis C, a large phase‑III trial found no overall increase in sustained virologic response, but patients who finished therapy had a lower relapse rate with thymalfasin.
Practical Outcomes
- For most biohackers, thymalfasin isn’t a stand‑alone cure for hepatitis; it might be used as an add‑on to approved antiviral regimens under medical supervision. The current evidence is modest, so it’s not a high‑priority supplement for longevity or performance unless you have chronic hepatitis and are working with a clinician.
Summary
Thymosin‑alpha‑1 (thymalfasin) can boost the immune system and may help the body fight hepatitis B and C when used together with standard antiviral drugs, but big studies show it doesn’t dramatically increase cure rates, only possibly lowers the chance of the virus coming back after treatment.
Abstract
Thymalfasin exhibited an immunomodulatory and a direct antiviral mechanism of action. The low rate of sustained response of chronic hepatitis with current therapies, underscores the need for new therapeutic options. It has been suggested that thymalfasin may have efficacy in the treatment of chronic hepatitis B and C. Pilots studies in patients with chronic hepatitis B treated with thymalfasin in combination with interferon or nucleoside analogue, showed a 70% complete sustained response rate. Studies in chronic hepatitis C patients, would indicate that thymalfasin in combination with standard or pegylated interferon with ribavirin may improve response rate in hepatitis C virus (HCV) naïve and nonresponder patients. However, a large phase-III randomized study conducted in Europe in HCV patients nonresponder to Peg-interferon with ribavirin, demonstrated that thymalfasin did not improve the rate of sustained virologic responses, but, in patients who completed therapy, thymalfasin significantly diminished the relapse rate. In conclusion, thymalfasin, in combination with the standard of care, may be helpful as an adjuvant in the treatment of patients with chronic hepatitis B and C.
Study Information
pubmed
2010
2010-05-01T00:00:00.000Z
10.1111/j.1749-6632.2010.05487.x
13
44